Precigen reported total revenue of $2.92 million for the third quarter of 2025, a 68% increase from $1.73 million in the same period last year. The jump was driven by the recognition of deferred revenue from the termination of an exclusive channel collaboration agreement and a 2.0 million increase in product and service revenue tied to the launch of its first FDA‑approved therapy for adult recurrent respiratory papillomatosis (PAPZIMEOS). The company’s revenue beat consensus estimates of $0.5 million to $0.9 million by a margin of roughly 224%.
Continue reading for full analysis...